MwanzoCMPS • NASDAQ
add
Compass Pathways PLC
$Â 4.80
Baada ya Saa za Kazi:(0.00%)0.00
$Â 4.80
Imefungwa: 6 Jun, 17:40:59 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$Â 4.53
Bei za siku
$Â 4.56 - $Â 4.99
Bei za mwaka
$Â 2.49 - $Â 8.54
Thamani ya kampuni katika soko
449.10M USD
Wastani wa hisa zilizouzwa
1.05M
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 41.17M | 16.06% |
Mapato halisi | -17.86M | 49.23% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.42 | 23.91% |
EBITDA | -41.13M | -16.15% |
Asilimia ya kodi ya mapato | -2.02% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 260.11M | -1.06% |
Jumla ya mali | 319.14M | 3.28% |
Jumla ya dhima | 123.67M | 148.17% |
Jumla ya hisa | 195.47M | — |
hisa zilizosalia | 93.56M | — |
Uwiano wa bei na thamani | 2.15 | — |
Faida inayotokana na mali | -38.63% | — |
Faida inayotokana mtaji | -49.67% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -17.86M | 49.23% |
Pesa kutokana na shughuli | -45.66M | -119.21% |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | 140.36M | 121.00% |
Mabadiliko halisi ya pesa taslimu | 95.02M | 122.85% |
Mtiririko huru wa pesa | -38.61M | -312.21% |
Kuhusu
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Ilianzishwa
13 Jun 2016
Tovuti
Wafanyakazi
166
